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ABSTRACT 
Objective: To investigate the effectiveness of high-dose corticosteroids in patients with severe leptospirosis, especially in reducing morbidity and 
mortality rates. 
Methods: Literature searches were conducted using PubMed® and SCOPUS®. One systematic review and one systematic review with meta-
analysis were selected from three chosen studies. 
Results: The systematic review from Rodrigo et al. only included qualitative synthesis from four interventional studies. Early administration of 
methylprednisolone can be beneficial; however, low number and poor methodological quality of the studies question the validity of this review. 
Duggal et al. stated that there was no significant difference in the therapeutic effects of early high-dose corticosteroids (P ≥ 0.05; 95% CI: 0.81–1.37), 
early low-dose corticosteroids (P ≥ 0.05; 95% CI: 0.3–1.03), and late low-dose corticosteroids (P ≥ 0.05; 95% CI: 0.11–2.52). Limited number of 
studies and high statistical heterogeneity, however, are major drawbacks for this review. 
Conclusion: Evidence about the role of high-dose corticosteroids in severe leptospirosis patients with pulmonary complications, especially their 
benefits, is still limited. Additional randomized, controlled trials with adequate statistical power still need to be conducted. 
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INTRODUCTION 
Leptospirosis is an acute infection caused by Leptospira spp. Its 
severity mainly depends on the virulence and toxins of the 
pathogens, as well as on the immune responses of the host. Acute 
Respiratory Distress Syndrome (ARDS) often occurs because of the 
loss of integrity of the epithelium or endothelium, and the release of 
cytokines. Consequently, the use of drugs that can decrease immune-
mediated reactions, such as corticosteroids, has been evaluated. 
Case Illustration 
A 19-year-old male patient was admitted to the inpatient ward with 
the chief complaint of fever for five days prior to hospital admission. 
Based on the history taken, the characteristics of his fever were 
sudden onset and continuously high body temperature without a clear 
trigger. Furthermore, the body temperature was not measured with 
appropriate devices. The patient also complained of abdominal pain 
and diarrhea for five days prior to hospital admission (three times a 
day, no mucus, no blood, yellowish brown color). The patient had been 
referred from the primary healthcare center because of a reduced 
platelet count (39000/µl). A history of previous hospitalization, 
similar clinical manifestation in the past, spontaneous bleeding, nausea 
and vomiting, decreased level of consciousness, seizures, cardiac 
disease, hematological problems, lung diseases, allergy, and previous 
trauma were denied. The patient was a farmer and often did not wear 
slippers when he worked. Recently, his neighborhood suffered from 
damage due to recurrent floods during the rainy season. The patient 
denied any consumption of medications. 
Two days after his hospitalization, the patient complained of 
recurrent cough with blood (approximately 1/3–1/2 volume of a 
cup) and of worsened weakness throughout his body. From physical 
examination, the patient appeared to be severely ill, and his level of 
consciousness was apathy. His blood pressure was 80/42 mmHg 
(hypotension), his heart rate was 153 times per minute 
(tachycardia), his respiratory rate was 42 times per minute 
(tachypnea), and he had very low oxygen saturation (64%). The 
patient also had anemic conjunctiva and ciliary suffusion in both 
eyes, crackles mixed with ronchi upon auscultation in both lungs, 
pain in the epigastric and right hypochondriac regions upon 
superficial abdominal palpation, and cold extremities. 
The most recent laboratory results showed low hemoglobin (8.5 
g/dl), low hematocrit (24%), low erythrocyte counts (2.92 × 
106
The patient was diagnosed with septic shock and severe 
leptospirosis with Acute Respiratory Distress Syndrome (ARDS). The 
patient was then admitted to the Intensive Care Unit (ICU) and 
intubated. Methylprednisolone 2 × 500 mg, a titration of 
norepinephrine and dobutamine, transamin 3 × 500 mg, and vitamin 
K, 3 × 1 ampul, were administered. 
/mcL), high white blood cell counts (23010/mcl), and low 
platelet counts (46000/mcl). The patient also had low blood sodium 
levels (127 mmol/l) and disturbed kidney functions (his blood urea 
level was 148 mg/dl, and his blood creatinine level was 6.8 mg/dl). 
His blood gas analysis indicated metabolic acidosis. Chest 
radiography showed infiltrates in both lungs. 
Background 
Leptospirosis is an acute infection, which can occur in humans and 
animals, and is caused by Leptospira spp. This disease was first 
discovered by Weil in 1886; thus, leading to the name Weil’s disease 
for severe leptospirosis. Mice have been known as the main carrier 
of this pathogen. Although leptospirosis is more common in tropical 
countries, the worldwide burden of the disease has become one of 
the main health concerns, nowadays. According to the World Health 
Organization (WHO), the number of severe leptospirosis cases 
worldwide is more than approximately 500,000 cases per year (10 
cases per 100,000 people living in tropical regions per year, and 0.1–
10 cases per 100,000 people living in temperate regions). Clinical 
manifestations usually vary from unspecific acute fever to severe 
manifestations such as kidney failure, icterus, spontaneous bleeding, 
respiratory failure, and vascular collapse [1]. 
The pathogenesis of leptospirosis begins when the patient comes in 
contact with soil or water that has been contaminated with the 
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pathogen. Through skin lesions, this pathogen will enter the 
bloodstream, actively breach the mucous membrane, and reach 
other organs (e. g., kidney, liver). Meanwhile, the immune system 
works against this pathogen by causing lysis of bacteria and release 
of antigens (glycolipoproteins, lipopolysaccharides, and endotoxins). 
These processes will lead to the activation of inflammatory cells (e. 
g., peripheral blood mononuclear cells) and to the induction of TNF-
alpha, IL-6, prostaglandin E2, and leukotriene B4 production, etc. 
Therefore, the severity of leptospirosis does not only depend on the 
virulence and toxins of the pathogens, but also on the intensity of the 
immune responses [1, 2]. 
The most severe manifestations of leptospirosis mainly occur in the 
lungs, kidneys, and the liver. ARDS or Acute Lung Injury (ALI) 
happen because of the loss of integrity of the epithelium or 
endothelium, and the release of cytokines (fig. 1). These factors 
cause edema and extravasation of proteins. In fatal cases, deposition 
of immunoglobulins in the alveolar septum may lead to pulmonary 
hemorrhage. As a result, until now, pulmonary hemorrhage has 
become the most common cause of death in patients with 
leptospirosis (rapid and severe manifestation with mortality rates 
up to 51%). In 17–50% of patients with leptospirosis, the most 
common clinical manifestation is hemoptysis [1, 3]. Glycolipoprotein 
that acts as a Na+/K+-ATPase inhibitor, is mainly involved in renal 
failure and electrolyte imbalance. In addition, inhibition of Na+/K+
 
-
ATPase may also lead to functional disturbances of the liver, 
hypoalbuminemia, increased nonesterified fatty acids (NEFAs), and 
hyperbilirubinemia in plasma [1]. 
 
Fig.  1: Pathogenesis of severe leptospirosis [2] 
 
As has been mentioned above, in severe leptospirosis, the immune 
response is highly correlated with multiple organ dysfunctions. A 
handful of studies have assessed the role of cell-mediated and 
humoral immunity in leptospirosis, and have detected 
immunochemical markers for the disease as well as several new 
mediators (e. g., human serum mannose-binding lectin) [4]. In a 
study by De Fost et al., markers of cell-mediated immunity, such as 
IFN-gamma-inducible-protein-10, granzyme B, and IFN-gamma-
induced monokine were increased in 44 patients with suspected 
severe leptospirosis [5]. As a result, the use of drugs that can 
decrease immune-mediated reactions, such as corticosteroids, has 
been evaluated in a considerable number of studies. This report will 
investigate further the effectiveness of high-dose corticosteroids in 
patients with severe leptospirosis, especially in reducing the 
morbidity and mortality rates of the patients. 
Clinical question 
Based on the case illustration, the clinical question is: “Is the 
administration of high-dose corticosteroids beneficial in decreasing 
mortality and morbidity rates from ARDS in patients with severe 
leptospirosis?” 
We will answer this question using the PICO process, which is an 
acronym of the following:  
• Population: Patients with severe leptospirosis 
• Intervention/Indicator: Administration of high-dose cortico-
steroids 
• Comparison: No administration of high-dose corticosteroids 
• Outcome: Reduced mortality and morbidity rates from ARDS 
MATERIALS AND METHODS 
Search strategy 
The articles were obtained from PubMed® and SCOPUS®. The input 
of PICO-based keywords was performed using Boolean Operators 
(table 1). 
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Table 1: Keywords used in the literature search 
Database Keywords Findings Selected 
PubMed (("high-dose corticosteroid"[Title/Abstract]) OR (“corticosteroid”[Title/Abstract]) AND 
("leptospirosis"[Title/Abstract]) OR ("severe leptospirosis"[Title/Abstract]) OR ("Weil’s 
disease"[Title/Abstract]))  
5 2 
Scopus TITLE-ABSTR-KEY(high-dose corticosteroid OR corticosteroid AND leptospirosis OR severe leptospirosis OR 




One systematic review and one systematic review with meta-
analysis were selected from three retrieved studies based on the 
similarity to the PICO, study populations, language, as well as 
inclusion and exclusion criteria of the studies. The article was 
critically appraised afterwards, using standard criteria for 
interventional research (fig. 2). 
 
Table 2: Critical appraisal of validity (Rodrigo et al. [2014]) [4] 
Indicator Explanation 
What clinical 
question (PICO) did 
the systematic review 
address? 
P: Adult patients with severe leptospirosis. 
I: Treatment with high-dose corticosteroids. 
C: Treatment without high-dose corticosteroids. 
O: Reduced mortality and morbidity due to pulmonary complications, including ARDS. 
Clinical question: Does treatment with high-dose corticosteroids result in lower mortality and morbidity due to pulmonary 
complications in patients with severe leptospirosis? 
Is it unlikely that 
important, relevant 
studies were missed? 
Unclear. 
• A comprehensive search strategy was applied to major bibliographic electronic databases (MEDLINE/PubMed, 
SciVerse Scopus). The search terms include all related keywords, including the alternative terms to expand the search 
strategy (e. g., “canicola fever”, “mudwater fever”, “canefield fever”, and “swamp fever” were included as alternative terms 
of “leptospirosis”). The literature search was conducted and reported according to the PRISMA checklist. 
• No date restrictions up to January 31st
• There were three reviewers who worked independently to evaluate all abstracts. All reviewers retrieved and read the 
full texts of these publications independently to confirm eligibility of the studies. 
, 2014. Information about language restrictions is not included in the review. 
• Clinical trials about leptospirosis in which one or more trial arms included corticosteroids were also included in this 
systematic review. 
• There were 260 records identified from the initial search (database searching and other sources, which are not 
specified by the authors). 152 records were screened after duplicates had been removed. After screening of title and 
abstract, only six full-text records were assessed for eligibility based on their relevance. Two out of six articles were 
excluded because the authors were unable to obtain the full text, and because one of them was an unpublished protocol for 
a randomized, controlled trial. Finally, four studies were included in the qualitative synthesis for this systematic review. 
• The authors also provided several case reports in this review, although they did not include the case reports in the 
main review because of the low quality of evidence and high possibility of publication bias.  
Were the criteria 




Inclusion criteria:  
- The authors did not mention detailed information about the type of study, participants, intervention, and outcome 
measures. The authors included all interventional studies, including clinical trials. 
Exclusion criteria:  
- Studies that were not relevant to the review, according to the authors of the review. 
- Studies where the full paper was not available.  
Were the included 
studies sufficiently 
validated for the type 
of question asked? 
Unclear. 
Assessing of the methodological quality of the studies included:  
- Three reviewers independently assessed the relevance to the review question. It is unclear, however, whether the 
formulation of the assessment questions was conducted and agreed to by all reviewers. 
- The authors did not mention whether they performed any assessment of risk of bias and applicability or not. 
- The authors did not comment on possible disagreements among the three review authors and on what kind of 
consensus was attempted (if any) to resolve them. 
Methodologic quality of included studies:  
- The authors considered all studies reviewed to have significant bias. 
- Different treatment regimens of corticosteroids were used in different studies. 
- There are only a small number of studies included in this systematic review, and these studies are of relatively poor 
methodological quality. 
- Four out of five studies are prospective case series with either a single arm study or a comparison between a treatment 
group and a historical cohort. 
- Three out of five studies had a small sample size with inadequate statistical power. 
- There are no concerns relating to the applicability of all included studies, based on the reference standard used. 
Were the results 
similar from study to 
study? 
Unclear. 
The studies included did not undergo quantitative synthesis; therefore, there is no statistical representation of 
heterogeneity available from the studies.  
 
Critical appraisal 
Applying the literature search strategy explained in fig. 2, the author 
found two systematic reviews. The first was written by Rodrigo et al. 
(2014), and the second was written by Duggal et al. (2015). Critical 
appraisal of these systematic reviews concerning their validity, 
importance, and applicability was performed using the 
recommendations and tools of the Centre for Evidence-Based Medicine, 
University of Oxford. Critical appraisal of applicability was conducted 
using the Critical Appraisal Skills Program (CASP) (table 2–4). 
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Fig.  2: Flow chart of literature searching (July 30th, 2018) 
 
Table 3: Critical appraisal of importance (Rodrigo et al. [2014]) [4] 
Indicator Explanation 
How are the 
results presented, 
and what are the 
main results? 
- The results are presented in table form. They consist of a qualitative synthesis of methodology, sample size, results, and 
limitations. 
- An additional table is provided to present brief descriptions of several case reports relevant to the systematic review. An 
analysis of these case reports, however, is not included in the main review. Eight out of ten case reports supported the use of 
intravenous steroids in patients with severe leptospirosis. Five out of the eight cases that showed successful steroid 
treatment in patients with pulmonary complications. 
- The authors generally recommended a short course of a moderate dose of steroids in severe leptospirosis patients with 
pulmonary complications, specifically ARDS, within 12 h of diagnosis. The use of higher doses of steroid is still questionable 
because one of the studies (Niwattayakul et al.) suggested a higher risk of nosocomial infections associated with high-dose 
steroid treatment. The authors also suggested the possibility of using empirical antibiotics if there is a high risk of nosocomial 
infections. The authors still addressed the limited availability of appropriate scientific evidence as the main hindrance toward 
adequate recommendation of this treatment. 
How precise are 
the results? 
Precision is not addressed statistically by the authors in this review. However, the authors mentioned a low quality of the 
evidence gathered from five studies included in the review, mainly because of their poor methodological quality, small 
sample size, differences in timing and dosing of corticosteroids among the studies, lack of clear outcome measures (definition 
of improved pulmonary conditions or pulmonary mortality, and overall mortality rates), and lack of clear and uniform, 
clinical and immunological diagnostic criteria of ARDS. 
 
Table 4: Critical appraisal of applicability (Rodrigo [2014]) [4] 
Indicator Explanation 
Can the results be 
applied to the local 
population? 
- As a developing country with tropical conditions and relatively high humidity, Indonesia also faces a problem of high 
leptospirosis incidence. Lack of awareness and low educational background may also contribute to the development of 
severe leptospirosis or multi-organ dysfunctions in some patients, who only seek medical treatment after severe 
manifestations have developed. 
- Almost all medical facilities in Indonesia use corticosteroids in various doses for inpatient and outpatient medical 
treatments. 
- Diagnosis of ARDS can be established through physical and radiological examinations in almost all medical facilities in 
Indonesia.  
Are the benefits 
worth the harms 
and costs?  
The benefit of high-dose corticosteroid treatment is still questionable because of insufficient evidence and recommendations. 
The increased risk of nosocomial infections with high-dose corticosteroid use still needs to be considered, especially if the 
medical facility is unable to provide adequate facilities and staff for strict monitoring afterwards.  
Conclusion Applicable in medical facilities with adequate standard operational procedures for intensive monitoring of the patients. 
 
Based on the critical appraisal of validity and importance, the article 
by Rodrigo et al. cannot be considered valid and important; 
however, this article can be applied well to the Indonesian 
population because of the high number of similar cases. There is an 
increased demand for therapeutic improvement to reduce morbidity 
and mortality rates. 
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Based on the critical appraisal of validity and importance, the article 
by Duggal et al. is considered valid and important. The content of 
this systematic review is also considered applicable to the 
population of Indonesia (table 5–7). 
 
Table 5: Critical appraisal of validity (Duggal et al. [2015]) [5] 
Indicator Explanation 
What clinical question 
(PICO) did the 
systematic review 
address? 
P: Adult patients with ARDS. 
I: Various types of pharmacologic therapy (cisatracurium, granulocyte macrophage colony-stimulating factor, early high-
dose corticosteroids, late low-dose methylprednisolone, early low-dose methylprednisolone, prostaglandin E1, 
salbutamol, surfactant, pentoxifylline, ketoconazole, lisofylline, interleukin-10, Xuebijing, simvastatin, activated protein C, 
ALT-836, dazoxiben, indomethacin, acyclovir, inactivated factor VIIa). 
C: Placebo or no therapy. 
O: Reduced all-cause mortality at or before three months after randomization. 
Clinical question: What are the effects of various pharmacologic therapies compared with placebo or no therapy on all-
cause mortality at or before three months after randomization in adult patients with ARDS? 
Is it unlikely that 
important, relevant 
studies were missed? 
Yes 
• A comprehensive search strategy involving several electronic databases (OVID versions of CENTRAL, CINAHL, 
MEDLINE, EMBASE) was used. A highly sensitive strategy was used by the authors to search for randomized, controlled 
trials from MEDLINE with several modifications to retrieve articles from EMBASE, CINAHL, and OVID versions of 
CENTRAL. The literature search for articles published before 2009 was conducted in the HEALTHSTAR database. A 
literature search was also performed on abstracts from conference proceedings (1994–2012) that had been published in 
the American Journal of Respiratory and Critical Care Medicine, Chest, Critical Care Medicine, and Intensive Care 
Medicine. 
• No language restrictions were applied. 
• There were two reviewers who worked independently to review all studies. The same reviewers also confirmed the 
eligibility of the studies by reading the full-text version of the articles. 
• There were two authors who independently extracted the data on participants, intervention, and outcome from all 
studies. A standardized form was filled out by the authors during the data extraction process. 
• Unclear data of the primary outcome were clarified by the authors of the original studies. 
• A systematic evaluation of the mechanistic quality of the pharmacologic therapies included in the studies was not 
performed; however, a methodological quality assessment was still conducted and agreed to by the reviewers. 
• After the initial phase of searching, 13461 articles (including conference abstracts and bibliographies) were obtained 
for screening. After screening for relevance to the topic of this systematic review, 118 studies were obtained. After the 
exclusion process, 58 studies (consisting of 58 trials, 21 classes of drugs, and 6635 patients with available data for 
primary outcomes) were chosen and assessed for eligibility.  
Were the criteria used 
to select articles for 
inclusion appropriate? 
Yes. 
Inclusion criteria:  
- Type of the study: randomized controlled trials. 
- Type of the participants: adult patients with any grade of severity of ARDS admitted to an ICU. Definition of mild ARDS 
or ALI can be used from previous nomenclature or based on American-European Consensus Conference (AECC) criteria 
or defined by the authors. 
- Type of intervention: comparison between pharmacological therapy and placebo, or no therapy. 
- Type of outcome measurement: all-cause mortality at or prior to three months after samples were randomized. 
Outcome measures consist of 90-days mortality, 60-days mortality, hospital mortality, and ICU mortality.  
Exclusion criteria:  
- Trials that require subgroup analysis. 
- Trials that evaluated enteral and parenteral nutritional interventions, fluid interventions, inhalation therapy with 
nitric oxide, mechanical ventilation, or medical oxygen. 
- Trials that compare two pharmacological agents into treatment group and placebo group.  
Were the included 
studies sufficiently 
valid for the type of 
question asked? 
Yes. 
Assessing the methodological quality of the studies included:  
- Methodological quality assessment was performed based on random sequence generation, allocation concealment, 
blinding of caregivers and outcome assessors, attrition bias, and analysis of primary outcomes (whether they are aligned 
with intention-to-treat principle and completeness of follow-up after intervention). 
- If there is any disagreement among the authors or reviewers during the process, the final decision is determined by 
consensus and with consultation of senior authors. 
- An acceptable reference standard was used in all studies. 
Were the results 
similar from study to 
study? 
No. Statistical heterogeneity of average sensitivities, specificities, and likelihood ratios of positive and negative test 
results using the I2 and chi-squared statistics were present. The results showed I2 values greater than 50% or P-values 
less than 0.1, which indicated high heterogeneity. Subgroup analysis based on MRI sequences was performed to explore 
heterogeneity further. 
 
Table 6: Critical appraisal of importance (Duggal et al. [2015]) [5] 
Indicator Explanation 
How are the results 
presented, and what 
are the main results? 
- Mortality data for each pharmacological agent were pooled, if the reviewers judged and identified clinically similar 
results from more than one study. If, in the study, samples were randomized to more than one dose, all doses would be 
grouped into one treatment arm. The results of the methodological quality appraisal were: clear description of random 
allocation in 24 (42.1%) trials; clear concealed allocation in 24 (42.1%) trials; low risk of performance bias due to blinding 
of caregivers in 44 trials (77.2%), and due to complete follow-up in 42 (73.7%) trials. Low risk of bias in all domains was 
found in 12 (21.1%) trials. 
- Comparisons between treatment arm and control arm were analyzed using relative risk (RR) and 95% confidence 
interval (CI). A statistically significant result was obtained when the P-value was less than 0.05. 
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- Meta-analysis was conducted in Review Manager 5.2 with inverse-variance random-effects models. These models 
generally are recommended because they better estimate the confidence intervals compared with the fixed-effect models.  
- Heterogeneity (I2
- Potential publication bias was assessed with a funnel plot, if the pooled analysis contained at least 10 trials. 
) was measured as a percentage of total variability among studies with regard to between-study 
heterogeneity. The thresholds used in this review are: low (25–49%), moderate (50–74%), and high (≥75%). 
- The major results of this systematic review showed:  
a) A statistically significant effect of cisatracurium in 431 patients on the 28-days mortality (RR = 0.66). 
b) No statistically significant effect of granulocyte macrophage colony-stimulating factor (RR = 0.89). 
c) No statistically significant effect of early high-dose corticosteroids (RR = 1.05). 
d) No statistically significant effect of late low-dose methylprednisolone (RR = 0.52). 
e) No statistically significant effect of N-acetylcysteine (RR = 0.81). 
f) No statistically significant effect of procysteine (RR = 1.41). 
g) No statistically significant effect of prostaglandin E1 (RR = 0.97). 
h) No statistically significant effect of surfactant (RR = 1.02). 
i) No statistically significant effect of a single trial with early low-dose methylprednisolone (RR = 0.56). 
j) No statistically significant effect of a single trial with salbutamol (RR = 1.16). 
-The authors also compared potential adverse events from each of the pharmacological agents. The major results are as 
follows:  
a) Cisatracurium: critical illness neuromyopathy; pneumothorax (P = 0.01), ICU-acquired paresis (P = 0.51). 
b) Granulocyte macrophage colony-stimulating factor: pulmonary complications, multi-organ failure, sepsis, infection (P = 
0.86). 
c) Late low-dose methylprednisolone: neuromyopathy (P = 0.2); neuromyopathy, which was reported as a serious adverse 
complication (P = 0.001); septic shock (P = 0.03); pneumonia (P = 0.05); higher mean serum glucose level (P = 0.27). 
d) Early low-dose methylprednisolone: newly acquired infection (P = 0.17); neuromuscular weakness (P = 1); 
hyperglycemia condition which requires insulin administration (P = 0.5). 
e) Procysteine: generalized edema (P = 0.002); hypernatremia (P = 0.057); prolonged QT interval (P = 0.03). 
f) Salbutamol: supraventricular tachyarrhythmias (P = 0.2). 
g) Surfactant: temporary hypoxemia (defined as oxygen saturation level less than 88%  higher incidence of hypoxemia in 
treatment groups than control groups); hypotension (defined as mean arterial pressure less than 60 mmHg higher 
incidence of hypotension in treatment groups). 
How precise are the 
results? 
The authors determined the precision of the results by comparing the 95% CI and heterogeneity of the relative risk among 
different trials using various pharmacological agents. The authors also compared risk of bias from the methodological 
quality assessment. 
a) Cisatracurium (95% CI = 0.5–0.87; I2
b) Granulocyte macrophage colony-stimulating factor (95% CI = 0.5–1.61; I
 = 0%->low heterogeneity. Two out of three trials had a high risk of bias due to 
inappropriate blinding of the caregivers). 
2
c) Early high-dose corticosteroids (95% CI = 0.81–1.37; I
 = 0%->low heterogeneity. Overall low risk of 
bias). 
2
d) Late low-dose methylprednisolone (95% CI = 0.11–2.52; I
 = 0%->low heterogeneity. Unclear risk of bias from random 
sequence generation and allocation concealment in two out of three trials). 
2
e) N-acetylcysteine (95% CI = 0.6–1.08; I
 = 79%->high heterogeneity. Unclear risk of bias from 
allocation concealment in one out of two trials). 
2
f) Procysteine (95% CI = 0.68–2.91; I
 = 0%->low heterogeneity. High risk of performance bias in one out of six trials). 
2
g) Prostaglandin E1 (95% CI = 0.79–1.19; I
 = 52%->moderate heterogeneity. Unclear risk of bias from random sequence 
generation and allocation concealment). 
2
h) Surfactant (95% CI = 0.9–1.14; I
 = 15%->low heterogeneity. Unclear risk of bias from random sequence 
generation and allocation concealment in five out of seven trials; unclear risk of attrition bias in two out of seven trials). 
2
i) Early low-dose methylprednisolone (95% CI = 0.3–1.03. Overall low risk of bias). 
 = 0%->low heterogeneity. Unclear risk of bias from random sequence generation in six 
out of eleven trials; unclear risk of bias from allocation concealment in seven out of eleven trials; high risk of performance 
bias in six out of eleven trials; high risk of attrition bias in one out of eleven trials; and unclear risk of attrition bias in four 
out of eleven trials. 
j) Salbutamol (95% CI = 0.68–1.96; I2 = 68%->high heterogeneity. Overall low risk of bias).  
 
Table 7: Critical appraisal of applicability (Duggal et al. [2015]) [5] 
Indicator Explanation 
Can the results be 
applied to the 
local population? 
- As a developing country with tropical conditions and relatively high humidity, Indonesia also faces a problem of high 
leptospirosis incidence. A lack of awareness and low educational background may also contribute to the development of 
severe leptospirosis or multi-organ dysfunctions in some patients, who only seek medical treatment after severe 
manifestations have developed.  
- Almost all medical facilities in Indonesia use corticosteroids in various doses for inpatient and outpatient medical 
treatments. 
- Diagnosis of ARDS can be established through physical and radiological examinations in almost all medical facilities in 
Indonesia.  
Are the benefits 
worth the harms 
and costs?  
The benefit of high-dose corticosteroid is still questionable because of insufficient evidence and recommendations. The 
increased risk of nosocomial infections and other serious adverse events upon corticosteroid use also still needs to be 
considered, especially if the medical facility is unable to provide adequate facilities and staff for strict monitoring afterwards.  
Conclusion Applicable in medical facilities with adequate standard operational procedures for intensive monitoring of patients. 
 
RESULTS 
The systematic review by Rodrigo et al. consists of four 
interventional studies with brief descriptions of 10 case reports with 
a similar topic. The aim of this systematic review is to evaluate 
benefits of high-dose corticosteroid treatment in patients with 
severe leptospirosis. The earliest study mentioned in this review is a 
single-arm, prospective, interventional pilot study by Ittyachen et al. 
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published in 2015. This study only included eight ICU patients with 
ARDS and leptospirosis, and provided no information about specific 
laboratory diagnostic criteria. All patients were treated with 
intravenous methylprednisolone (initial dose: 4 × 40 mg; mostly for 
four days), standard treatment, and noninvasive ventilation. The 
investigators concluded that methylprednisolone is a life-saving 
adjuvant when combined with standard treatment and noninvasive 
ventilation in patients with ARDS and leptospirosis because 87% of 
the patients survived and managed to recover completely after two 
weeks of treatment [4]. 
Another prospective study from this systematic review is a study by 
Kularatne et al. published in 2011. This study describes the results of 
78 severe leptospirosis patients treated with bolus intravenous 
methylprednisolone (500 mg daily for the first three days, continued 
with oral methylprednisolone, 8 mg daily for five days) and 
compared with retrospective cohort with one year duration of 
treatment. The investigators diagnosed leptospirosis with the 
Microscopic Agglutination Test (MAT). The investigators also 
classified the severity of organ impairment with a scoring system 
that ranged from zero to six. If the score was at least two, 
administration of methylprednisolone was required. Ten patients 
were excluded from the study because they were terminally ill. In 
patients with a score of four who were treated with 
methylprednisolone, the survival rate was 100%. This rate was 
significantly higher (P < 0.001) than with the patients with a similar 
score who were not treated with methylprednisolone (38%). 
However, no significant difference in the survival rate was observed 
in patients with a score of five or six (severe organ impairment) 
treated with methylprednisolone [4]. 
In the study by Shenoy et al., the investigators also used bolus 
intravenous methylprednisolone in 30 leptospirosis patients with 
pulmonary complications. The diagnosis of leptospirosis was 
confirmed with IgM ELISA (Enzyme-Linked Immunosorbent Assay) 
in this article, while the diagnosis of ARDS was confirmed by clinical 
manifestation or diffuse pulmonary infiltrates from radiological 
examination. A comparison was made between the group that 
received intravenous methylprednisolone (bolus, 1 g daily for the 
first three days, continued with oral prednisolone, 1 mg/kg daily for 
seven days) and the group that received only standard treatment. 
The investigators compared the survival rates and severity of 
pulmonary involvement using ALI and Acute Physiology and Chronic 
Health Evaluation III (APACHE) scores. The results showed 
significantly higher mortality rates (P<0.05) in the group treated 
with standard treatment (62%) than with the group that received 
corticosteroids (18%), except for patients who had four organ 
systems complications (pulmonary, hepatic, renal, hematological). In 
addition, the requirement of ventilator support was lower in the 
group that received corticosteroids. The investigators also found 
that there was a significantly better (P<0.005) response to 
corticosteroids in the presence of moderate-to-severe lung injury 
(ALI score >2.5 and APACHE III score >60). Because all deceased 
patients in the group treated with corticosteroids died more than 12 
h after they had suffered from difficulty of breathing, the 
investigators suggested that more benefits could be achieved in 
early administration of corticosteroids [4]. 
The last study in the systematic review by Rodrigo et al. is a 
prospective, randomized, controlled trial of desmopressin and high-
dose dexamethasone as an adjunctive treatment compared with 
standard treatment in severe leptospirosis patients with pulmonary 
complications. Sixty-eight patients were divided equally into three 
treatment groups: one group was treated with desmopressin (0.3 
mcg/kgBW in 50 ml saline over 30 min daily per infusion), one 
group with dexamethasone (200 mg daily for the first three days, 
continued with 1 mg/kg/day oral prednisolone for four days). A 
confirmation of the diagnosis was made with Polymerase Chain 
Reactions (PCR) and MAT. Only 76% of enrolled patients were 
finally confirmed as suffering from leptospirosis. The investigators 
concluded that there was no significant difference in mortality rates 
between the groups according to the intention-to-treat per protocol 
analysis. No significant differences in other outcome measures 
including duration of mechanical ventilation and bleeding were 
observed [4]. 
The second systematic review discussed in this manuscript was 
published by Duggal et al. in 2015. This review consists of 58 
randomized, controlled trials with 21 classes of pharmacological 
agents, involving 6635 patients. This review aims to study the effect 
of various pharmacological agents in adult patients with ARDS 
compared with placebo or no therapy. The outcome measure is all-
cause mortality at or before three months after the patients are 
randomized (classified into 90-days mortality, 60-days mortality, 
hospital mortality, and ICU mortality). ARDS and ALI were diagnosed 
using the criteria defined by the AECC. 
Overall, a wide range of pharmacological agents were examined in this 
review, including: prostaglandin-E1
  
 (seven trials), N-acetylcysteine 
(six trials), early high-dose corticosteroids (three trials), late low-dose 
corticosteroids (two trials), early low-dose corticosteroids (one trial), 
surfactant (eleven trials), neutrophil elastase inhibitors (six trials), 
cisatracurium (three trials), intravenous salbutamol (two trials), 
granulocyte macrophage-colony stimulating factor (two trials), 
procysteine (two trials), dazoxiben (one trial), acyclovir (one trial), 
indomethacin (one trial), pentoxifylline (one trial), interleukin-10 (one 
trial), ketoconazole (one trial), lisofylline (one trial), activated protein 
C (one trial), inactivated factor VIIa (one trial), simvastatin (one trial), 
Xuebijing (one trial), inhaled albuterol (one trial), and anti-tissue 
factor antibody or ALT-386 (one trial) [5]. The statistical analysis of 
the comparison between treatment and control arms is based on 
relative risk, 95% confidence interval, and determination of P-value. In 
addition, meta-analysis and measurement of heterogeneity were 
conducted (table 8). 
Table 8: Statistical analysis of the comparison of the effects of each pharmacological agent and placebo, or no therapy in adult patients 
with ARDS from all randomized, controlled trials included in this review [5] 
Pharmacological agents Relative risk (RR) P-value 95% Confidence interval (CI) I2 (Heterogeneity) 
Cisatracurium 0.66 <0.05 0.5–0.87 0% 
Granulocyte macrophage colony-stimulating factor 0.89 ≥0.05 0.5–1.61 0% 
Early high-dose corticosteroids 1.05 ≥0.05 0.81–1.37 0% 
Late low-dose corticosteroids 0.52 ≥0.05 0.11–2.52 79% 
Early low-dose corticosteroids 0.56 ≥0.05 0.3–1.03 – 
N-acetylcysteine 0.81 ≥0.05 0.6–1.08 0% 
Procysteine 1.41 ≥0.05 0.68–2.91 52% 
Prostaglandin E1 0.97 ≥0.05 0.79–1.19 15% 
Surfactant 1.02 ≥0.05 0.9–1.14 0% 
Salbutamol 1.16 ≥0.05 0.68–1.96 68% 
 
The investigators also described the potential risk of bias for each study. 
Potential bias is mainly classified as bias from random sequence 
generation, bias from allocation concealment, performance bias, and 
attrition bias. The authors also described potential adverse effects that 
had been found in all studies and included how statistically significant 
the possibility of having each of the adverse effects is (table 9) [5]. 
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Table 9: Potential adverse effects of various pharmacological agents for treating ARDS in adult patients [5] 
Pharmacological agents Potential adverse effects Clinical/Statistical significance 
Cisatracurium Critical illness neuromyopathy 1/18 patients per group 
 Pneumothorax P-value = 0.01 
 ICU-acquired paresis P-value = 0.51 
Granulocyte macrophage colony-
stimulating factor 
Pulmonary complications, multi-organ failure, 
sepsis, infection 
P-value = 0.86 
Late low-dose corticosteroids Neuromyopathy  P-value = 0.2 
 Severe neuromyopathy P-value = 0.001 
 Septic shock P-value = 0.03 
 Pneumonia P-value = 0.05 
 Higher mean serum glucose level P-value = 0.27 
Early low-dose corticosteroids Newly-acquired infections P-value = 0.17 
 Neuromuscular weakness P-value = 1.0 
 Hyperglycemia P-value = 0.5 
Procysteine Generalized edema  P-value = 0.002 
 Hypernatremia P-value = 0.057 
 Prolonged QT interval P-value = 0.03 
Salbutamol Supraventricular tachyarrhythmia P-value = 0.2 
Surfactant Temporary hypoxemia (oxygen saturation<88%) 51.9% in treatment group and 25.2% in control 
group 
 Hypotension (mean arterial pressure<60 mmHg) 34.1% in treatment group and 17.1% in control 
group 
 
As a whole, the results of both systematic reviews are applicable to the 
Indonesian population because of its increasing number of severe 
leptospirosis cases (table 10). In addition, many medical facilities in 
Indonesia, especially in big cities, have used corticosteroids in various 
doses for both inpatient and outpatient therapeutic regimens. Additional 
examinations to confirm the diagnosis of ARDS (for example: radiological 
examination and arterial blood gases analysis) are also widely used. 
Therefore, in the presence of adequate facilities, health professionals, 
and good standard operational procedures to monitor patients closely, 
the use of high-dose corticosteroids will be beneficial. 
 
Table 10: Determination of level of evidence for each of the studies based on validity criteria 
Article Year Validity Level of 
evidence PICO Appropriate 
searching 





Rodrigo, et al. 2014 (+) (-) (-) (-) (?) 3a 
Duggal, et al. 2015 (+) (+) (+) (+) (-) 1a 
Legends: (+) = mentioned clearly in the article; (-) = in not mentioned or unclear explanation in the article levels of evidence are determined based 
on the criteria from the Oxford centre of evidence-bases medicine  
 
Table 11: Scoring of acute lung injury (ALI) [6] 
Components Values 
Chest X-Ray score  
No alveolar consolidation 0 
Alveolar consolidation confined to 1 quadrant 1 
Alveolar consolidation confined to 2 quadrants 2 
Alveolar consolidation confined to 3 quadrants 3 
Alveolar consolidation in all 4 quadrants 4 
Hypoxemia score (arterial oxygen tension to inspired oxygen concentration ratio)  
PaO2/FiO2 0  ≥ 300 
PaO2/FiO2 1  225–299 
PaO2/FiO2 2  175–224 
PaO2/FiO2 3  100–174 
PaO2/FiO2 4 <100 
Positive end expiratory pressure score (PEEP) if the patient is ventilated  
PEEP ≥5 cmH2 0 O 
PEEP 6–8 cmH2 1 O 
PEEP 9–11 cmH2 2 O 
PEEP 12–14 cmH2 3 O 
PEEP ≥15 cmH2 4 O 
Respiratory system compliance score (if available)  
Compliance ≥80 ml/cmH2 0 O 
Compliance 60–79 ml/cmH2 1 O 
Compliance 40–59 ml/cmH2 2 O 
Compliance 20–39 ml/cmH2 3 O 
Compliance ≤19 ml/cmH2 4 O 
Final scores (dividing the aggregate sum by the number of components used)  
No lung injury 0 
Mild-to-moderate lung injury 0.1–2.5 
Severe lung injury (ARDS) >2.5 
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The author evaluated two systematic reviews, with one of the 
reviews contains a meta-analysis. The first systematic review, 
from Rodrigo et al., only included a qualitative synthesis from 
four studies. The clinical question addressed by that article is 
similar to the clinical question in this manuscript. Unfortunately, 
because the authors did not explain the search process in the 
method section in more detail, it is still unclear whether 
important and relevant studies were missed, which puts the 
validity of this article into question. The authors also did not 
specify any inclusion criteria for the type of study, participants, 
intervention, and outcome measures. In addition, the small 
number of studies and their poor methodological quality (e. g., 
small sample size, which lowers the adequacy of statistical 
power and increases the risk of bias) also contributed to the 
questionable validity of the conclusions from this systematic 
review [4]. 
Uniformity of treatment regimens of corticosteroids and definition of 
pulmonary involvement also becomes a problem for both systematic 
reviews. In the systematic review by Rodrigo et al., for example, the dose 
of dexamethasone, which had been used in the study by Niwattayakul et 
al., was high in comparison with the dose of methylprednisolone in the 
study by Shenay et al. Differences in doses in both studies might 
contribute to statistically significant higher numbers of nosocomial 
infections in the study by Niwattayakul et al. Other confounding factors, 
which might result from these differences, were frequency of treatment, 
duration of treatment, oral drugs and/or antibiotics [4]. To define the 
severity of pulmonary complications, Rodrigo et al. used ALI (table 11) 
[6] and APACHE III [4, 6] scores, while Duggal et al. used criteria from the 
AECC (table 12) [5, 7]. 
 
Table 12: Recommended criteria by the AACE on Acute Lung Injury (ALI) and acute respiratory distress syndrome (ARDS) [7] 
Criteria Timing Oxygenation Chest radiograph Pulmonary artery wedge pressure 
ALI Acute 
onset. 




≤18 mmHg when measured or no clinical evidence of 
left atrial hypertension. 
ARDS Acute 
onset. 




≤18 mmHg when measured or no clinical evidence of 
left atrial hypertension. 
 
Although the evidence and recommendations provided by Rodrigo et 
al. were limited, the authors suggested that early administration 
(within 12 h of diagnosis) of methylprednisolone may be beneficial in 
severe leptospirosis patients with pulmonary complications. This 
conclusion, however, contradicts the conclusion from the systematic 
review by Duggal et al., which stated that there was no significant 
difference in therapeutic effects of early high-dose corticosteroids, 
early low-dose corticosteroids, and late low-dose corticosteroids. It 
needs to be kept in mind, however, that even though Duggal et al. were 
one step ahead of Rodrigo et al. by providing a quantitative and 
qualitative synthesis of randomized controlled trials, the systematic 
review itself still needs further improvement due to the limited 
number of studies (only one study for early low-dose 
methylprednisolone) and high statistical heterogeneity from two 
studies with late low-dose methylprednisolone [4, 5]. 
To conclude, evidence about the role of high-dose corticosteroids in 
severe leptospirosis patients with pulmonary complications, especially 
about their benefits, is still limited. Additional randomized, controlled 
trials with adequate statistical power still need to be conducted. 
Several methodological qualities need more careful attention, such as: 
clinical and immunological diagnostic criteria; exclusion of infectious 
processes with similar clinical manifestation; clear definition of 
disease severity and uniformity of scoring systems; uniformity of 
doses and duration of corticosteroid treatment; clarity and uniformity 
in outcome measurements. Studies with an adequate sample size and 
study type must also be considered. 
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